

Neonatal Pharmacology Conference 2025:

Incorporating Evidence-Based Practice into Clinical Decision Making

November 12-15, 2025



Disclosure Statement

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education anyone involved in planning or presenting this educational activity will be required to disclose any financial relationships with any ineligible companies. *An ineligible company is any entity whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.* This information is listed below. Any financial relationships with these ineligible companies have been mitigated by the MUSC Office of CME. Speakers who incorporate information about off-label or investigational use of drugs or devices will be asked to disclose that information at the beginning of their presentation.

The following information has been disclosed:

Presenters/Planners/Moderators and Planners with NO financial relationships with Ineligible Companies:

Andy Atz, MD

Rubin Auijla, MD

Christine Baxter, DNP

Jessica Benes, DNP-BC

David Bundy, MD

John Cahill, MD

Florian Capobianco, DO

Alison Chapman, MD

Monica Conetta

Carmen Dooley, APRN, MSN, NNP

Kylie Hopkins, DNP

Jeffrey King, MD

Chung Lee, MD

Mark Lockett, MD

Amber Monroe, DNP, NNP

Remberto Paulo, MD

Rita Ryan, MD

Heidi Steflik, MD

Stephen Thacker, MD

Katherine Vincent, MD

Christine Woodburn, DO

Presenters/Planners/Moderators and Planners with financial relationships with Ineligible Companies which have been mitigated:

Candi Jump, DO

Speaker with Alcresta Therapeutics

Michael Morowitz, MD

Consultant with IBT Pharmaceuticals

Ravi Patel, MD

Unrestricted equipment Grant with Medtronic

Katherine Twombly, MD

Research Grant with Kaneka